23 C
New York
Saturday, June 6, 2026

Tag: hematology

newssourceFORcompanyinformationcontent1marketreleases

China’s Leading Innovative Drug Developer for Allergic and Autoimmune Diseases LongBio Pharma Lists on Hong Kong Stock Exchange

SHANGHAI, June 5, 2026 /PRNewswire/ -- LongBio Pharma, a portfolio company of Qiming Venture Partners and a leading innovative drug developer for allergic and...

China’s Leading Innovative Drug Developer for Allergic and Autoimmune Diseases LongBio Pharma Lists on Hong Kong Stock Exchange

SHANGHAI, June 5, 2026 /PRNewswire/ -- LongBio Pharma, a portfolio company of Qiming Venture Partners and a leading innovative drug developer for allergic and...

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and...

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

DRI Healthcare Reports Second Quarter 2025 Results

Subsequent to the end of the quarter, completed the previously announced transaction to internalize its investment management functionPortfolio assets generate Total Income of $44.1...

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  

Ad hoc announcement pursuant to Art. 53 LR

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

         - Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis -

Florida Cancer Specialists & Research Institute Welcomes Medical Oncologist & Hematologist Nikhita Kathuria-Prakash, MD To Columbia County

FORT MYERS, Fla., Aug. 1, 2025 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce that medical oncologist and hematologist Nikhita...

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Agios Pharmaceuticals today announced financial results and updates for the second quarter ended June 30, 2025.

Sumitomo Pharma America Announces that the European Medicines Agency Has Granted Orphan Drug Designation to Nuvisertib (TP-3654) for the Treatment of Myelofibrosis

– Nuvisertib (TP-3654), an oral investigational highly selective PIM-1 kinase inhibitor, is being evaluated in patients with relapsed or refractory myelofibrosis (MF) – MARLBOROUGH, Mass.,...

Germany IVD Analyzers Market Outlook to 2033 – Hematology Analyzers, Polymerase Chain Reaction Systems, Point of Care Analyzers Revenue Trends, Segment Volumes, Pricing, and...

Explore the future of the Germany IVD Analyzers market with our comprehensive report, covering key data from 2018 to 2033. Analyze segments like Hematology, PCR Systems, and POC Analyzers. Create winning strategies, understand market dynamics, and seize growth opportunities. Ideal for strategy development. 
Explore the future of the Germany IVD Analyzers market with our comprehensive report, covering key data from 2018 to 2033. Analyze segments like Hematology, PCR Systems, and POC Analyzers. Create winning strategies, understand market dynamics, and seize growth opportunities. Ideal for strategy development.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsHematology

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers